We investigated the clinical significance of ERp57 in the progression of cervical cancer.
mRNA and protein expression of ERp57 in cervical neoplasias were examined.
ERp57 mRNA expression was significantly decreased in cervical cancers. Immunohistochemistry revealed that ERp57 expression in 123 cervical cancers was down-regulated compared to cervical intraepithelial neoplasias or normal tissues (p < 0.001). Low ERp57 expression was significantly associated with worse overall survival (HR = 12.19, p = 0.018).
Low ERp57 expression independently predicts a poor outcome for patients with cervical cancer, supporting the notion that ERp57 may be a promising novel cancer target.